Through this collaboration, Lilly will gain access to Ailux's AI-powered bispecific antibody engineering platform, which ...

Eli Lilly (NYSE: LLY) is part of this group. On Sept. 16, the drugmaker announced plans to build a $5 billion facility in ...

In today’s ACT Brief, we explore how Eli Lilly’s orforglipron could become the first oral GLP-1 therapy reviewed under FDA’s new national priority program, and examine emerging regulatory and ethical ...

The drug, which Lilly in-licensed four years ago and is designed to inhibit a protein known as P2X7, did not meet the company ...

Before being discontinued, the P2X7 receptor blocker had cleared a master protocol study in chronic pain, though Eli Lilly ...

Eli Lilly & Company (NYSE:LLY) ranks among the best fundamental stocks to buy right now. Eli Lilly & Company (NYSE:LLY) revealed plans on September 16 to build a $5 billion manufacturing facility in ...

Oct 14 (Reuters) - Eli Lilly & Co (LLY.N), opens new tab on Wednesday said other trials of its experimental coronavirus antibody therapy remain on track after a government-run study testing the ...

"Eli Lilly buys Adverum in eye disease gene therapy punt" was originally created and published by Pharmaceutical Technology, ...

Sept 16 (Reuters) - Eli Lilly and Co (LLY.N), opens new tab on Wednesday said a single infusion of its experimental antibody treatment reduced the need for hospitalization and emergency room visits ...

Korean biosimilar specialist Celltrion has penned a deal worth more than $740 million biobucks for two preclinical autoimmune ...

WASHINGTON -- They're not cures, but experimental antibody drugs like the one President Donald Trump was given are among the most promising therapies being tested for treating and preventing ...

Reuters published an article speculating that orforglipron, Eli Lilly's next-generation obesity drug currently in development, could earn Food and Drug Administration (FDA) approval by the end of this ...